Synapse - Genitourinary Oncology Service

Search Within

Genitourinary Oncology Service

Results (5695)

The PCCTC imaging data capture toolset: An analysis of its impact on prostate cancer clinical trial accuracy and workload

Meeting Abstract

Dennis, E. R.; Fox, J. J.; Larson, S. M.; Farrelly, J. S.; Schwartz, L. H.; Schöder, H.; Haupt, E. C.; Borwick, L. S.; Scher, H. I.; Morris, M. J.
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

A randomized, double-blind, phase III trial comparing ipilimumab versus placebo following radiotherapy (RT) in patients (pts) with castration-resistant prostate cancer (CRPC) who have received prior treatment with docetaxel (D)

Meeting Abstract

Drake, C. G.; Scher, H. I.; Gerritsen, W. R.; Ezzeddine, R.; Fitzmaurice, T. F.; Cuillerot, J.; Chin, K. M.; Gagnier, P.
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

Genomic analysis of circulating tumor cells (CTC) from patients with castration-resistant prostate cancer (CRPC) as predictive biomarkers

Meeting Abstract

Danila, D. C.; Anand, A.; Yao, J.; Gierszewska, M.; Kramer, M.; Muller, S.; Fleisher, M.; McCombie, W. R.; Scher, H. I.
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

Patient-reported outcomes (PROs) in a phase III AXIS trial of axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC)

Meeting Abstract

Cella, D.; Escudier, B.; Rini, B. I.; Chen, C.; Bhattacharyya, H.; Tarazi, J. C.; Rosbrook, B.; Kim, S.; Motzer, R. J.
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

Initial analytic validation of automated bone scan measures for treatment response assessment in patients with metastatic castration-resistant prostate cancer (CRPC)

Meeting Abstract

Chu, G. H.; Brown, M. S.; Kim, H. J.; Auerbach, M.; Poon, C.; Ramakrishna, B.; Vidovic, A.; Gjertson, D. W.; Morris, M. J.; Larson, S. M.; more...
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

Automated tumor detection on bone scans for treatment response assessment

Meeting Abstract

Brown, M. S.; Chu, G. H.; Kim, H. J.; Auerbach, M.; Poon, C.; Vidovic, A.; Ramakrishna, B.; Gjertson, D. W.; Morris, M. J.; Larson, S. M.; more...
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

Effect of sunitinib (SU) administration on post-treatment survival in patients with metastatic renal cell carcinoma (mRCC) treated on the upfront randomized phase III trial of sunitinib or interferon alfa (IFN)

Meeting Abstract

Blagoev, K. B.; Wilkerson, J.; Stein, W. D.; Motzer, R. J.; Bates, S. E.; Fojo, A. T.
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

Design of a phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy targeting HER2/neu, in patients with surgically resected urothelial cancer at high risk of recurrence

Meeting Abstract

Bajorin, D. F.; Sharma, P.; Sims, R. B.; Sandler, A.; Lerner, S. P.
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

Fluorodeoxyglucose (FDG) positron emission tomography (PET) as an indicator of disease progression for patients with castration-resistant metastatic prostate cancer (CRMPC)

Meeting Abstract

Baklajian, A.; Dennis, E. R.; Buddle, J. R.; Fox, J. J.; Schoder, H.; Morris, M. J.; Larson, S. M.; Scher, H. I.
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

Phase II trial of gemcitabine, carboplatin, and bevacizumab (Bev) in patients (pts) with advanced/metastatic urothelial carcinoma (UC)

Meeting Abstract

Balar, A. V.; Milowsky, M. I.; Apolo, A. B.; Ostrovnaya, I.; Iasonos, A.; Trout, A.; Regazzi, A. M.; Garcia-Grossman, I. R.; Gallagher, D. J.; Bajorin, D. F.
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save